Priority Research Papers:
Functional consequence of the MET-T1010I polymorphism in breast cancer
Metrics: PDF 3152 views | HTML 3776 views | ?
Abstract
Shuying Liu1,2, Funda Meric-Bernstam3, Napa Parinyanitikul1, Bailiang Wang1, Agda K. Eterovic2, Xiaofeng Zheng4, Mihai Gagea5, Mariana Chavez-MacGregor1, Naoto T. Ueno1,6, Xiudong Lei7, Wanding Zhou4, Lakshmy Nair1, Debu Tripathy1, Powel H. Brown8, Gabriel N. Hortobagyi1, Ken Chen4, John Mendelsohn9, Gordon B. Mills2 and Ana M. Gonzalez-Angulo1,2
1 Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5 Department of Veterinary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
6 Section of Breast Cancer Translational Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
7 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
8 Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
9 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence:
Shuying Liu, email:
Keywords: MET mutations, Breast Cancer, Malignant transformation
Received: September 09, 2014 Accepted: December 24, 2014 Published: December 31, 2014
Abstract
Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer. Expression of MET-T1010I in the context of mammary epithelium increases colony formation, cell migration and invasion in-vitro and tumor growth and invasion in-vivo. A selective effect of MET-T1010I as compared to wild type MET on cell invasion both in-vitro and in-vivo suggests that the MET-T1010I SNP may alter tumor pathophysiology and should be considered as a potential biomarker when implementing MET targeted clinical trials.
![Creative Commons License](/images/80x15.png)
PII: 3094